Please login to the form below

Not currently logged in
Email:
Password:

Damien McDevitt moves from GSK to Acadia Pharmaceuticals

Takes up position as SVP, corporate development at the US biopharma firm

Acadia Damien McDevittUS biopharmaceutical company Acadia Pharmaceuticals has appointed Damien McDevitt (pictured) as senior vice president of corporate development.

He joins the San Diego-based firm from GlaxoSmithKline, where he spent more than two decades, most recently serving as VP, head of business development for R&D extended therapy areas and head of its R&D West Coast Satellite.

Prior to that, McDevitt held positions with increasing responsibility within worldwide business development at GSK Ventures and Anti-Infectives Discovery.

At Acadia, which focuses on the development and commercialisation of medicines for central nervous system (CNS) disorders, McDevitt will report to the company’s president and chief executive officer Steve Davis.

He said: “We are thrilled to welcome Damien to the team. Damien has extensive experience in business development, licensing and strategic partnering, and he has completed dozens of value-creating transactions. This expertise, combined with his strong strategic and technical background, will be of great value as we continue to explore the potential for expanding our CNS portfolio.”

Meanwhile, Acadia’s SVP, technology development and operations Jim Nash will retire in January. The company’s former SVP, strategy and business development Bob Mischler will assume responsibilities for technology development and operations in addition to continuing his strategy responsibilities in the new role of SVP, strategy and technology operations.

21st December 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics